drugset / Trial / NCT06192784
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2
Unknown
36 enrolled
Tongji Hospital
Chinese Cooperative Group of Liver Cancer · collabGeneplus-Beijing Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of drug eluting beads-transcatheter arterial chemoembolization combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2023-12-09
- Primary completion
- 2025-01-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Pucotenlimab | Monoclonal antibody | 200 mg | — |